Literature DB >> 9815851

Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer.

B H Bochner1, D Esrig, S Groshen, M Dickinson, N Weidner, P W Nichols, D G Skinner, R J Cote.   

Abstract

The purpose of this investigation was to evaluate the relationship between tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer. We studied 161 patients with invasive transitional cell carcinoma of the bladder who had previously undergone radical cystectomy. Analysis was performed to determine the presence of p53 nuclear accumulation and extent of tumor-associated angiogenesis. p53 status identified a group of patients at high risk for tumor progression (p53-altered tumors), and microvessel density determinations added additional prognostic information by identifying a subset of aggressive tumors within the wild-type p53 subgroup. At 5 years, patients with tumors exhibiting no evidence of p53 alterations and low microvessel counts demonstrated 3% recurrence and 88% survival, compared to 43% recurrence and 59% overall survival for patients with intermediate vessel counts and 61% recurrence and 43% overall survival for patients with the highest vessel counts (P < 0.001 and P = 0.003, respectively). Angiogenesis also provides additional prognostic information to patients with tumors that demonstrate p53 alterations. An association between angiogenesis and p53 status did exist (P = 0. 05); however, 27% of the tumors that showed no evidence of p53 alterations exhibited high microvessel counts, and 26% of tumors with evidence of p53 alterations had low microvessel counts. Tumor-associated angiogenesis adds additional useful prognostic information to that which is obtained from p53 status in patients with invasive transitional cell carcinoma of the bladder. Although an association between p53 status and the degree of angiogenesis was identified, other factors appear to play a role in the regulation of tumor-induced neovasularization.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815851

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

1.  Serum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma.

Authors:  Qi Niu; Zhao-You Tang; Zeng-Chen Ma; Lun-Xiu Qin; Lian-Hai Zhang
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

Review 2.  Molecular substratification of bladder cancer: moving towards individualized patient management.

Authors:  Anirban P Mitra
Journal:  Ther Adv Urol       Date:  2016-03-28

Review 3.  The role of angiogenesis in prostate and other urologic cancers: a review.

Authors:  J I Izawa; C P Dinney
Journal:  CMAJ       Date:  2001-03-06       Impact factor: 8.262

4.  Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis.

Authors:  Ali Canoğlu; Cağatay Göğüş; Yaşar Bedük; Diclehan Orhan; Ozden Tulunay; Sümer Baltaci
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

5.  Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma.

Authors:  Francisco Ayala de la Peña; Keizo Kanasaki; Megumi Kanasaki; Neelima Tangirala; Genta Maeda; Raghu Kalluri
Journal:  J Biol Chem       Date:  2011-03-09       Impact factor: 5.157

Review 6.  Molecular targets and targeted therapies in bladder cancer management.

Authors:  Ramy F Youssef; Anirban P Mitra; Georg Bartsch; Peter A Jones; Donald G Skinner; Richard J Cote
Journal:  World J Urol       Date:  2008-11-28       Impact factor: 4.226

7.  Angiogenesis in urinary bladder carcinoma as defined by microvessel density (MVD) after immunohistochemical staining for Factor VIII and CD31.

Authors:  Khaled El Gehani; Lamia Al-Kikhia; Naziha Mansuri; Kari Syrjänen; Omran Al-Fituri; Adam Elzagheid
Journal:  Libyan J Med       Date:  2011-03-31       Impact factor: 1.657

8.  Gene therapy for bladder cancer using E1B-55 kD-deleted adenovirus in combination with adenoviral vector encoding plasminogen kringles 1-5.

Authors:  J-L Hsieh; C-L Wu; M-D Lai; C-H Lee; C-S Tsai; A-L Shiau
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.